La lecture en ligne est gratuite
Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres
Télécharger Lire

ITG and NTP Cooperation - Milestone in Global Security of Supply for Radioisotope Industry

2 pages
ITG and NTP Cooperation - Milestone in Global Security of Supply for Radioisotope Industry PR Newswire GARCHING NEAR MUNICH, Germany, June 8, 2012 GARCHING NEAR MUNICH, Germany, June 8, 2012 /PRNewswire/ -- ITG Isotope Technologies Garching GmbH (ITG) - specialist in innovative radioisotopes - expands its nuclear reactor and technology
Voir plus Voir moins
ITG and NTP Cooperation - Milestone in Global
Security of Supply for Radioisotope Industry
PR Newswire
GARCHING NEAR MUNICH, Germany, June 8, 2012
GARCHING NEAR
MUNICH, Germany
,
June 8, 2012
/PRNewswire/ --
ITG Isotope Technologies Garching GmbH (ITG) - specialist in innovative
radioisotopes - expands its nuclear reactor and technology network in line with
its strategy to guarantee global security of supply.
In
May 2012
, ITG - a fully-owned subsidiary of ITM Isotopen Technologien
München AG (ITM) based in
Germany
- and NTP Radioisotopes SOC Ltd (NTP) -
a subsidiary of the South African Nuclear Energy Corporation (NECSA) - agreed
on a substantial collaboration regarding radioisotopes. The cooperation is an
important milestone in ensuring a reliable supply of high quality radioisotopes
for
Africa
and
Brazil
. As a first step, NTP and ITG have agreed on a technology
transfer for the unique isotope ITG Lu-177 n.c.a. (non carrier added). In
addition, ITG will expand its already well-established global reactor network by
cooperating with NECSA's Safari-1 nuclear reactor.
Lutetium-177 plays a key role in nuclear medicine in the treatment of
neuroendocrine tumors, and has displayed strong growth potential. In
comparison to other production routes, every atom of the ITG Lu-177 n.c.a. is
radioactive. This results in specific activity many times higher than similar
products, therefore rendering treatments more effective. The contamination
with the long lived isomer Lu-177m is negligible. NTP has in-licensed the
production technology and will hence be the exclusive distribution partner for
ITG products in
Africa
.
Safari-1 nuclear reactor is one of only five reactors in the world, which together
produce 98% of the world's radionuclides for the medical sector. Steffen
Schuster, CEO of ITM states: "In the recent past, SAFARI-1 has been
instrumental in securing the supply of radiopharmaceuticals (via NTP) into the
world market when reactors were down due to unforeseen problems. It sends a
strong signal to those companies working with Lu-177-based therapies - global
supply is guaranteed and the agreement serves as proof of the value of our
production expertise.".
ITG is a well-established company in the supply of next generation isotopes and
technology. The company provides highly effective radioisotopes, such as the
ITG Lu-177 n.c.a., the ITG Ge-68/Ga-68 Generator and the ITG W-188/Re-188
Generator, as well as corresponding customized devices. ITG is renowned for its
dedicated team providing outstanding reliability in both quality and supply. ITG
has an esteemed global network of sales partners and strategic cooperations.
NTP is recognized as a leading global supplier of radioisotopes. NTP
manufactures a range of radioisotope products for use in downstream medical
devices and procedures as well as in industry. They have maintained consistent
growth in over 60 countries and in customers served.
The alliance of ITG and NTP will further enhance their international
competitiveness as well as reinforce their prominent position as a reliable and
attractive partner for their customers worldwide.
For further information and investor enquiries please contact:
ITG Isotope Technologies Garching GmbH, Dr. Richard Henkelmann, Managing
Director, +49-89-289-13946, Richard.Henkelmann@itg-garching.de
Un pour Un
Permettre à tous d'accéder à la lecture
Pour chaque accès à la bibliothèque, YouScribe donne un accès à une personne dans le besoin